Abstract
The INternational VErapamil SR/trandolapril STudy (INVEST) randomized 22,576 CAD, hypertension patients to a verapamil SR (Ve) or atenolol (At) strategy. Flexible dose titration and addition of trandolapril (T) and/or HCTZ targeted BP control and organ protection. There was no difference by strategy for primary outcome (PO; first occurrence of death, nonfatal MI, or nonfatal stroke). An exploratory method was developed to analyze effect of drug-dose combinations on the PO. Prescription data were collected electronically for over 61,835 patient years. Average daily doses of drugs received by patient until PO or censoring were fit as time-dependent variables in a Cox proportional hazards model. Strategy, two interaction terms and two ratios measuring the proportion of time the first two drugs in the strategy were co-prescribed were also included. Exploratory analysis of INVEST prescription database estimates relative risk of PO for specific drug dose combinations. For complex patients with hypertension and CAD, combination therapy with Ve/T or At/HCTZ reduces the risk of adverse CV events compared with Ve or At monotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
